These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 27223151)

  • 21. Bispecific antibody mimicking factor VIII.
    Nogami K
    Thromb Res; 2016 May; 141 Suppl 2():S34-5. PubMed ID: 27207420
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving Emicizumab. Interim guidance from UKHCDO Inhibitor Working Party and Executive Committee.
    Collins PW; Liesner R; Makris M; Talks K; Chowdary P; Chalmers E; Hall G; Riddell A; Percy CL; Hay CR; Hart DP
    Haemophilia; 2018 May; 24(3):344-347. PubMed ID: 30070072
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Emicizumab for routine prophylaxis to prevent bleeding episodes in patients with hemophilia A.
    Díaz-Ricart M; Isola IM; Escolar G
    Drugs Today (Barc); 2018 Oct; 54(10):591-600. PubMed ID: 30398480
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prospective, observational study of plasma-derived factor VIII/von Willebrand factor in immune tolerance induction: the PRISM registry.
    Kruse-Jarres R; Gilsenan A; Spears J; Kaye JA
    Haemophilia; 2015 Mar; 21(2):e122-e124. PubMed ID: 25623889
    [No Abstract]   [Full Text] [Related]  

  • 25. Curing Hemophilia: Repeated Treatments versus a One-Off Fix.
    Li N; Kaczmarek R
    Mol Ther; 2020 May; 28(5):1229-1230. PubMed ID: 32304671
    [No Abstract]   [Full Text] [Related]  

  • 26. Inhibitor development in haemophilia A: the role of von Willebrand factor/factor VIII concentrates.
    Goudemand J
    Haemophilia; 2007 Dec; 13 Suppl 5():47-51. PubMed ID: 18078397
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing.
    Mancuso ME; Mahlangu JN; Pipe SW
    Lancet; 2021 Feb; 397(10274):630-640. PubMed ID: 33460559
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emerging Therapeutic Strategies in the Treatment of Hemophilia A.
    Muczynski V; Christophe OD; Denis CV; Lenting PJ
    Semin Thromb Hemost; 2017 Sep; 43(6):581-590. PubMed ID: 28750425
    [No Abstract]   [Full Text] [Related]  

  • 29. Outcomes in children with hemophilia A with inhibitors: Results from a noninterventional study.
    Oldenburg J; Shima M; Kruse-Jarres R; Santagostino E; Mahlangu J; Lehle M; Selak Bienz N; Chebon S; Asikanius E; Trask P; Mancuso ME; Jiménez-Yuste V; von Mackensen S; Levy GG
    Pediatr Blood Cancer; 2020 Oct; 67(10):e28474. PubMed ID: 32776489
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Emicizumab: a paradigm shift in hemophilia treatment].
    Nogami K
    Rinsho Ketsueki; 2020; 61(5):536-541. PubMed ID: 32507821
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lower-dose emicizumab prophylaxis: can less be more?
    Srivastava A; Iorio A
    J Thromb Haemost; 2024 Apr; 22(4):922-925. PubMed ID: 38521578
    [No Abstract]   [Full Text] [Related]  

  • 32. Utilization of emicizumab in the treatment of a case of acquired hemophilia A.
    Ocaña Gómez MÁ; Esquivel Negrín J; Ríos De Paz M; De Dios García MD
    Farm Hosp; 2024; 48(1):45-47. PubMed ID: 37468348
    [No Abstract]   [Full Text] [Related]  

  • 33. Verification and Comparison of Chromogenic Factor VIII Activity Assays in Patients With Hemophilia Treated With and Without Emicizumab.
    Lee MY; Lee WI; Kang SY; Kim MH; Park YS
    Ann Lab Med; 2023 Jan; 43(1):96-99. PubMed ID: 36045063
    [No Abstract]   [Full Text] [Related]  

  • 34. Do we need all that emicizumab?
    Lehtinen AE; Lassila R
    Haemophilia; 2022 Mar; 28(2):e53-e55. PubMed ID: 34970820
    [No Abstract]   [Full Text] [Related]  

  • 35. Adult haemophilia A patients with inhibitors: successful immune tolerance induction with a single FVIII/VWF product.
    Rangarajan S; Jiménez-Yuste V; Santagostino E
    Haemophilia; 2014 Nov; 20(6):e414-7. PubMed ID: 25333452
    [No Abstract]   [Full Text] [Related]  

  • 36. Development of VIII inhibitors beyond 50 exposure days to rFVIII during prophylactic emicizumab therapy.
    Mitani Y; Honda M; Mizushima Y; Mori M; Fukuoka K; Oshima K; Arakawa Y; Taira K; Tanami Y; Koh K
    Haemophilia; 2023 Nov; 29(6):1653-1655. PubMed ID: 37707369
    [No Abstract]   [Full Text] [Related]  

  • 37. Emicizumab, a humanized bispecific antibody to coagulation factors IXa and X with a factor VIIIa-cofactor activity.
    Kitazawa T; Shima M
    Int J Hematol; 2020 Jan; 111(1):20-30. PubMed ID: 30350119
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emicizumab-kxwh: First Global Approval.
    Scott LJ; Kim ES
    Drugs; 2018 Feb; 78(2):269-274. PubMed ID: 29357074
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recurrence of a high-titre factor VIII inhibitor in a haemophilia A patient on emicizumab prophylaxis.
    Doshi BS; Witmer CM
    Haemophilia; 2021 Jul; 27(4):e551-e553. PubMed ID: 33866659
    [No Abstract]   [Full Text] [Related]  

  • 40. Inhibitor development in two cousins receiving full-length factor VIII (FVIII) and FVIII-Fc fusion protein.
    Ragni MV; Alabek M; Malec LM
    Haemophilia; 2016 Sep; 22(5):e462-4. PubMed ID: 27501368
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.